medigraphic.com
ISSN 0016-3813 (Print)

2002, Number S1

<< Back Next >>

Gac Med Mex 2002; 138 (S1)

Bone Marrow Transplant. The Mexican Experience

I. How to Achieve the Center Effect? Experience with Hematopoietic Cell Transplant.
II. Post-Bone Marrow Transplant Immunologic Reconstruction.
III. Results of the Mexican Protocol (Monterrey/Pu

Enrique Gómez-Morales, Alejandro Limón-Flores, Guillermo Ruíz-Argüelles, Jorge Vela-Ojeda

Language: Spanish
References: 54
Page: 135-144
PDF size: 68.52 Kb.


Text Extraction

No abstract


REFERENCES

  1. GRD, Una guía práctica para médicos. IMSS 2001. p. 57.

  2. Lee SJ, Anasetti C, Kuntz KM, et al. The cost and cost-effectiveness of unrelated donor bone marrow transplantation for chronic phase myelogenous leukemia. Blood 1998;92:4047-4052.

  3. Hosenpud JD, Breen TJ, Edwards EB, et al. The effect of transplant center volume on cardiac transplant outcome. JAMA 1994;271:1844-1849.

  4. Sosa JA. Bowman HM, Gordon TA, et al. Importance of hospital volume in the overall management of pancreatic cancer. Ann Surg 1998;28:429-438.

  5. Sainsbury R, Haward B, Rider L, et al. Influence of clinical workload and patterns of treatment on survival from breast cancer. Lancet 1995;3455:1265-1270.

  6. European Group for Bone Marrow Transplantation. Allogeneic bone marrow transplantation for leukemia in Europe. Lancet 1988;8599:1379-1382.

  7. Horowitz MM, Prezepiorka D, Champlin RE, et al. Should HLA-identical sibling bone marrow transplants for leukemia be restricted to large centres? Blood 1992;79:2771-2774.

  8. Matsuo K, Hamajima N, Morishima Y, Harada M. Hospital capacity and post-transplant survival after allogeneic bone marrow transplantation: analysis of data from the Japan Society for Hematopoietic Cell Transplantation. Bone Marrow Transplant 2000;26:1061-1067.

  9. INEGI. México: Estadísticas del Sector Salud y Seguridad. Social, Cuaderno # 17, 2001.

  10. Arana-Trejo RM, Gómez-Morales E, Rubio-Borja ME, et al. Cytogenetic findings in 303 Mexican patients with de novo acute myeloblastic leukemia . Arch Med Rese 1997;28(2):209.

  11. Gómez-Morales E, Sánchez-Valle E, Pizzuto-Chávez-J. De la teoría a la práctica en trasplante de células hematopoyéticas, experiencia del hospital de especialidades, del CMN Siglo XXI. Aguirre-Gas H, editor. Actualidades médico-quirúrgicas II, México: Editorial Prado. 2001. p. 219-258.

  12. Robertson Parkman, KI. Weinberg. Immunological reconstitution following hematopoietic stem cell transplantation. In:Thomas ED, Blume KG, Forman SJ, editors. Hematopoietic cell transplantation. Blackwell Science, Inc,1999.

  13. Atkinson K. Reconstruction of the haemopoietic and immune system after marrow transplantation. Bone Marrow Transplant 1990;5;209-226.

  14. Keever CA, Small TN, Flomenberg N, et al. Immune reconstitution following bone marrow transplantation: comparison of recipients of T cell depleted with recipients of conventional marrow grafts. Blood 1989;73;1340-1350.

  15. Friedrich W., O’Reilly RJ, Kosiner B et al. T lymphocyte reconstitution in recipients of bone marrow transplants with and without GVHD: imbalances of T cell populations having unique regulatory and congnitive functions. Blood 1982; 59:696-701.

  16. Forman SJ, Nocker P, Gallagher M et al. Pattern of T cell reconstitution following allogeneic bone marrow transplantation for acute hematological malignancies. Transplantation 1982; 34;96-98.

  17. Atkinson K. T cell sub-populations defined by monoclonal antibodies after HLA identical sibling marrow transplantation. Activated and functional subsets of the helper-inducer and the cytotoxic-suppressor sub-populations defined by two colour fluorescense flow cytometry. Bone Marrow Transplant 1986;1;121-132.

  18. Ault KE, Antin JH, Ginsburg D, et al. Phenotype of recovering lymphoid cell populations after marrow transplantation. J Exp Med 1985;161;1483-1502.

  19. Noel DR, Whiterspoon RP, Storb, et al. Does graft-versus-host disease influence the tempo of immunologic recovery after allogeneic human marrow transplantation? An observation on long term survivors. Blood 1978;51;1087-1105.

  20. Storek J., Whiterspoon RP. Immunologic reconstitution after hematopoietic stem cell transplantation. In: Atkinson K, editor. Clinical bone marrow and blood stem cell transplantation. Cambridge, UK: Cambridge University Press; 2000;111-146.

  21. Jan Storek, Ansamma Joseph, German Espino, et al. Immunity of patients surviving 20 to 30 years after allogeneic or syngeneic bone marrow transplantation. Blood 2001;(98)13; 3505-3512.

  22. Giralt S, Estey E, Albitar M, van Besien K, et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeoablative therapy. Blood 1997;89:4531-4536.

  23. Slavin S, Nagler A, Naparstek E, Kapelushnik Y, et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematological diseases. Blood 1998;91:756-763.

  24. Carella AM, Lerma E, Dejana A, Corsetti MT, Celesti L, Bruni R, Benvenuto F, Figari O, Parodi C, Carlier P, Florio G, Lercari G, Valbonesi M, Casarino L, De Stefano F, Geniram A, Venturino M, Tedeschi L, Palmieri G, Piaggio G, Podesta M, Frassoni F, Van Lint MT, Marmont AM, Bacigalupo A. Engraftment of HLA-matched sibling hematopoietic stem cells after immunosuppressive conditioning regimen in patients with hematologic neoplasias. Haematologica 1998; ¿83:904-909.

  25. Vindelov L. Allogeneic bone marrow transplantation with reduced conditioning. Eur J Haematol 2001;66:73-82.

  26. Ruiz-Argüelles GJ. Outpatient programs of myeloablative chemotherapy, autologous and allogeneic bone marrow transplantation. Haematologica 2000; 85:1233-1234.

  27. Ruiz-Argüelles GJ. “The Mexican approach” to conduct non-myeloablative stem cell transplantation. Eur J Haematol 2002, (In press).

  28. Gómez-Almaguer D, Ruiz-Argüelles GJ, Ruiz-Argüelles A, González-Llano O, Cantú OE, Hernández NE.: Hematopoietic stem cell allografts using a non-myeloablative conditioning regimen can be safely performed on an outpatient basis. Bone Marrow Transpl 2000;25:131-133.

  29. Ruiz-Argüelles GJ, Gómez-Almaguer D, Ruiz-Argüelles A, González-Llano O, Cantú OG, Jaime-Pérez JC. Results of an outpatient-based stem cell allotransplant program using non-myeloablative conditioning regimens. Am J Hematol 2001; 66:241-244.

  30. Ruiz-Argüelles GJ, Ruiz-Argüelles A, Gómez-Almaguer D, López-Martínez B, Abreu-Díaz G, Bravo G, Jaime-Pérez JC. Features of the engraftment of allogeneic hematopoietic stem cells using reduced-intensity conditioning regimens. Leukemia Lymphoma 2001;42: 145-150.

  31. Ruiz-Argüelles GJ, López-Martínez B, Estrada E, Marín-López A, Bravo G, Hernández JM. Autologous and allogeneic peripheral blood stem cell transplantations may be conducted without transfusion of blood products. Blood 2001;98 (Suppl):351b.

  32. Ruiz-Argüelles GJ, Gómez-Almaguer D, López-Martínez B. Why are mini-transplants being conducted worldwide? Rev Invest Clín Méx 2001;53:110-111.

  33. Ruiz-Argüelles GJ, Gómez-Almaguer D, López-Martínez B, Ponce-de-León S, Cantú-Rodríguez OG, Jaime-Pérez JC. No cytomegalovirus-related deaths after non-ablative stem cell allografts. Hematology 2002 (In press).

  34. Ruiz-Argüelles GJ, Gómez-Almaguer D, López-Martínez B, Cantú-Rodríguez OG, Jaime-Pérez JC, González-Llano O, Herrera-Garza JL. Results of an allogeneic non-myeloablative stem cell transplantation program in patients with chronic myelogenous leukemia. Int J Haematol, 2002 (In press).

  35. Graber CJ, Almeida KNF, Childs R. Cytomegalovirus reactivation and disease in myeloablative versus non-myeloablative allogeneic stem cell transplantation. Program and abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy. September 17-20, 2000. Toronto, Ontario, Canada. Abstract 779.

  36. Mossad SB, Avery RKJ, Longworth DL., Kuczkowski EM, McBee M, Pohlman BL, Sobecks RA, Kalaycio ME, Andresen SW, Macklis RM, Bolwell BJ. Infectious complications within the first year after nonmyeloablative allogeneic peripheral blood stem cell transplantation. Bone Marrow Transplant. 2001;28:491-495.

  37. Reynoso EE, Sánchez-Cruz P, Verástegui E, Sobrevilla PJ, García F, Mohar A. Prevalence of cytomegalovirus infection among patients and blood donors at the Instituto Nacional de Cancerología, México. Blood 1991;78 (Suppl 1): 354a.

  38. Ruiz-Argüelles GJ, Ruiz-Argüelles A, Pérez-Romano B, Marín-López A, Delgado-Lamas JL. Non-cryopreserved peripheral blood stem cells autotransplants for hematological malignancies can be performed entirely on an outpatient basis. Am J Hematol 1998; 58:161-164.

  39. Ruiz-Argüelles GJ, Apreza-Molina MG, Alemán-Hoey DD, Gómez-Almaguer D, Marín-López A, Mercado-Díaz L. Outpatient supportive therapy after induction to remission therapy in adult acute myelogenous leukaemia (AML) is feasible: a multicentre study. Eur J Haematol 1995;54:18-20.

  40. Weissinger F, Sandmaier BM, Maloney DG, Bensinger WI, Gooley T, Storb R. Decreased transfusion requirements for patients receiving nonmyeloablative compared witrh conventional peripheral blood stem cell transplants from HLA-identical siblings. Blood 2001:98:3584-3588.

  41. Ruiz-Argüelles GJ, López-Martínez B, Santillán-Olea MR, Abreu-Díaz G, Reyes-Núñez V, Ruiz-Argüelles A, Garcés-Eisele J. Follow-up of hemopoietic chimerism in individuals given allogeneic hemopoietic stem cell allografts using an immunosuppressive, non-myeloablative conditioning regimen: a prospective study. Leukemia Lymphoma 2002 (In press).

  42. Thomas ED. Hematopoietic stem cell transplantation. Sci Am 1995;272:38-47.

  43. Ruiz-Arguelles GJ. Simplification, not demystification nor trivialization of stem cell transplantation. Haematologica 2001; 86;E07.

  44. Chandy M. Management of hematological diseases in developing countries: socio-economic aspects. In: Schechter GP, Hoffman R, Schrier SL, editors. Hematology 1999. The American Society of Hematology Education Program Book. Washington, D.C., USA; 1999. p. 73-76

  45. Ruiz-Argüelles GJ, Ruiz-Reyes G. El tratamiento de las leucemias en países en desarrollo. In: Ruiz-Argüelles GJ, San-Miguel JF, editors. Actualización en Leucemias. México: Editorial Médica Panamericana; 1996. p. 147-151.

  46. Childs R, Clave E, Contentin N. Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation: full donor T-cell chimerism precedes alloimmune responses. Blood 1999;94:3234-3241.

  47. McSweeney PA, Storb R. Mixed chimerism: preclinical studies and clinical applications. Biol Blood Marrow Transplant 1999;5:192-203.

  48. Ruiz-Argüelles GJ. Outpatient programs of myeloablative chemotherapy, autologous and allogeneic bone marrow transplantation. Haematologica 2000;85:1233-1234.

  49. Quesenberry PJ, Stewart FM, Becker P. Stem cell engraftment strategies. Ann NY Acad Sci 2001;938:54-62.

  50. Keating MJ, O´Brien S, Robertson LE. The expanding role of fludarabine in hematologic malignancies. Leuk Lymphoma 1994;14(Suppl 2):11-16.

  51. Giralt S, Estey E, Albitar M. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood 1997;89:4531-4536.

  52. Slavin S, Nagler A, Naparstek E. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998;91:756-763.

  53. Little MT, Storb R. The future of allogeneic hematopoietic stem cell transplantation: minimizing pain, maximizing gain. J Clin Invest 2000;105(12):1679-1681.

  54. Khouri IF, Keating M, Korbling M. Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J Clin Oncol 1998;16:2817-2824.




2020     |     www.medigraphic.com